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Conclusions: In subjects with radiographic knee OA of defined 
pain severity, significant relief is effected by D at 2 & 12 weeks 
according to two validated, widely-used OA instruments, where- 
as A is not signficantly different han P. 
Group wo Week 0 Week 2 % better p W e e k 
12 % better p 
D WOp 200=102 140==105 30 0.0001 146¢101 27 0,002 
WOt 97±50 706=536 27 0,001 719=516 26 0.0001 
A WOp 211±86 206±101 2 0,671 187±122 11 0.134 
WOt 964±375 906¢-453 0 0.919 889=529 8 0,191 
P WOp 199±111 197±119 1 0,878 183¢123 8 0,420 
WOt 994±520 947=516 5 0.221 878±521 12 0.085 
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IMPROVED QUALITY-OF-LIFE (QoL) WITH ETORICOXIB 
COMPARED WITH PLACEBO IN PATIENTS WITH 
OSTEOARTHRITIS 
SP Curtis, A Leung, DJ Watson, D Ramey, S Kong, S Harper 
Merck Research Laboratories, Rahway, NJ, USA 
Aim: Etoricoxib, a highly selective cyclooxygenase-2 (COX-2) 
inhibitor, has demonstrated efficacy in OA and RA. We compared 
the efficacy of etoricoxib, naproxen, and placebo on QoL 
(Medical Outcomes Trust SF-36) in OA patients in the 12-week 
portion of 2 phase III trials. 
Methods: Replicate, multicenter, randomized, parallel-group, 
double-blind studies enrolled a total of 997 patients with OA of 
the knee or hip who had worsening symptoms (flare) upon dis- 
continuation of OA therapy. Baseline measures were obtained at 
the flare visit, prior to randomization to etoricoxib 60 mg once 
daily (N=446), naproxen 500 mg twice daily (N=439), or placebo 
(N=112). Clinical efficacy data were collected at 2, 4, 8, and 12 
weeks. Analyses were done on all patients randomized. The SF- 
36 domain and Physical Component Summary (PCS) and Mental 
Component Summary (MCS) scores were calculated using estab- 
lished methods (on a 0-100 scale; higher scores are better). Mean 
scores change from baseline to week-12, adjusted for baseline 
value and primary study joint (knee vs hip), were compared 
across treatments. 
Results: Etoricoxib was superior to placebo and comparable 
with naproxen on all three primary efficacy measures (WOMAC 
pain and physical function subscales, and patient global assess- 
ment of disease status), and was well tolerated over 12 weeks. 
For the QoL measure, mean baseline scores for the etoricoxib 
and placebo arms were similar for each domain, the PCS, and 
MCS. The difference (p-value) in the domain scores [mean 
change between etoricoxib and placebo] were: physical function- 
ing 7.7 (<0.001); role physical 12.5 (<0.001); pain 9.7 (<0.001); 
general health perceptions 4.4 (<0.001); mental health 2.5 (0.08); 
role emotional 13.1 (<0.001); social functioning 7.6 (<0.001); vital- 
ity 6.6 (<0.001). For the PCS and MCS, the difference between 
etoricoxib and placebo was 3.6 (<0.001) and 2.3 (0.008), respec- 
tively. Similar results were found comparing naproxen to placebo. 
Differences between etoricoxib and naproxen were slight and not 
statistically different on any of the SF-36 scores. 
Conclusion: In this study, patients with OA of the hip or knee 
treated with etoricoxib 60 mg once daily for 12 weeks had statis- 
tically significantly greater improvement in 7 of 8 SF-36 domain 
scores and in both the Physical and Mental Component Summary 
scores compared with placebo. These improvements are consis- 
tent with the OA efficacy results observed in this study. 
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PRESCRIPTION HABITS FOR OSTEOARTHRITIS PATIENTS: 
RESULT OF A NATION-WIDE PHARMACO-EPIDEMIOLOGI- 
CAL SURVEY ON 10000 PATIENTS 
P Hiliquin, _/3 Fautrel 2, F-A Allaert 3 S Rosenberg 1, p Coste 4 , M 
Rossignol b 
~HOpital Gilles de Corbeil, Corbeil; 2 Rheumatology, HSpital Pitie- 
Salpetriere Pads; 3 Cenbiotech, Dijon~ ;~ Laboratoires 
Pharmascience M Courbevoie; France; Department of 
Epidemiology, McGill University, Montreal (QC), Canada 
Osteoarthritis (OA) in real life settings is often difficult to study, 
especially in France where no reliable database exists to explore 
prescription habits of physicians. 
Methods: In 2000, a nation-wide survey in more than 5000 physi- 
cians, either general practitioners (90.3%) or rheumatologists 
(9.7%), representative of the French medical demography, was 
conducted. Each recruited the first two patients consulting for 
hip, knee or hand OA after the onset of the survey. 
Results: Medical information was available for 10412 patients, 
whose OA was diagnosed on both clinical and radiological find- 
ings in 84.5%. Their mean age was 66.2 ± 10.2 years with a sex 
ratio F:M of 1.96. 
Prescriptions 
Analgesics 94.4% 
NSAID 77.7% 
Anti-OA agents* 89.8% 
Topical NSIAD 60.2% 
Steroid joint injection in past 19.7% 
year 
Hyaluronic acid injection in 1.5% 
past year 
Physiotherapy 28.4% 
* such as glucosamine sulfate. 
Frequency 
Renewal New 
93.1% 6.9% 
71.1 % 28.9% 
65.4% 34.6% 
(Mean number t .7 ±0.9) 
Massage: 77.7% 
Muscle strengthening:50.6% 
Both analgesics and NSAIDs were prescribed as needed vs daily 
in the majority of patients (67.4 and 70.4%). There was no major 
difference in the use of these medications according to the fre- 
quency of pain, the type of symptoms and the site of OA. 
Moreover, 28.8% of OA patients reported use of complementary 
and alternative medicine. The most commonly used were 
mesotherapy 48.4% (subcutaneous injections of medication), 
acupuncture 23.4%, herbal remedies 15.6%, homeopathy 
14.8%. 
Conclusion: This study provides a representative overview of the 
prescription habits of French physicians for OA. It emphasizes the 
great frequency of therapeutic ombinations, with minor differ- 
ences according to the symptoms or the site of OA. Local thera- 
py, especially steroid injections, and physiotherapy were also 
commonly used. 
